PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Core Insights - PTC Therapeutics is a global biopharmaceutical company focused on rare diseases and disorders with high unmet needs [2] - The company has a robust commercial portfolio with six marketed products and an innovative R&D pipeline, particularly in oral small molecule splicing programs [2] Product Launch and Performance - The year 2025 has been marked by the successful U.S. and EU approval of Sephience, an oral therapy for phenylketonuria (PKU) [3] - The launch of Sephience has shown strong momentum, contributing to the company's path towards cash flow breakeven and beyond [3]